Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26673811

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2016 Feb 20
First author
Dreyling M

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Feb 20;387(10020):750
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2016 Feb 20;387(10020):728-9. doi: 10.1016/S0140-6736(15)01040-5.
    note
    Source null
    related pmid
    26673812
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2016 Feb;13(2):65. doi: 10.1038/nrclinonc.2015.231.
    note
    Source null
    related pmid
    26718106
    relationship
    Comment in

Authors and identifiers

  1. name
    Dreyling M
    type
    Author
  2. name
    Jurczak W
    type
    Author
  3. name
    Jerkeman M
    type
    Author
  4. name
    Silva RS
    type
    Author
  5. name
    Rusconi C
    type
    Author
  6. name
    Trneny M
    type
    Author
  7. name
    Offner F
    type
    Author
  8. name
    Caballero D
    type
    Author
  9. name
    Joao C
    type
    Author
  10. name
    Witzens-Harig M
    type
    Author
  11. name
    Hess G
    type
    Author
  12. name
    Bence-Bruckler I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dreyling M
    type
    Author
  2. name
    Jurczak W
    type
    Author
  3. name
    Jerkeman M
    type
    Author
  4. name
    Silva RS
    type
    Author
  5. name
    Rusconi C
    type
    Author
  6. name
    Trneny M
    type
    Author
  7. name
    Offner F
    type
    Author
  8. name
    Caballero D
    type
    Author
  9. name
    Joao C
    type
    Author
  10. name
    Witzens-Harig M
    type
    Author
  11. name
    Hess G
    type
    Author
  12. name
    Bence-Bruckler I
    type
    Author
bibliography ids
  1. nci-bib-5fb79c56bbfb58dd5a326c13
book metadata
content sha256
e91a8f07206645c9105fb4b6d3ae744dd5753a37f95b6180522c71c0bb1f0db9
document type
citation
dois
  1. 10.1016/S0140-6736(15)00667-4
electronic publication date
display
2015 Dec 7
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26673811
immutable id
pubmed:26673811@e91a8f07206645c9105fb4b6d3ae744dd5753a37f95b6180522c71c0bb1f0db9
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10020
name
Lancet (London, England)
nlm unique id
2985213R
pages
770-8
volume
387
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2016 Feb 20;387(10020):750
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2016 Feb 20;387(10020):728-9. doi: 10.1016/S0140-6736(15)01040-5.
    note
    Source null
    related pmid
    26673812
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2016 Feb;13(2):65. doi: 10.1038/nrclinonc.2015.231.
    note
    Source null
    related pmid
    26718106
    relationship
    Comment in
outcomes validated
false
pmid
26673811
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
b7899e4518b9dc9793b81ee1e5083f872458335a53b62f626a5126be3f20e22c
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2016 Feb 20
precision
day
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26673811/
title
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice